

ForPatients

by Roche

Huntington Disease (HD)

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Trial Status
Completed

Trial Runs In
17 Countries

Trial Identifier
NCT03761849 GENERATION HD1
BN40423

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03761849 GENERATION HD1 BN40423
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=25 Years & <= 65 Years

Healthy Volunteers
No
